title: [Progress in the treatment of 155 children with rhabdomyosarcoma obtained in one center between 1962-1990].
abstract: The results of treating 155 children with rhabdomyosarcoma using protocols that (RMS) changing over the years between 1962-1990 in reported to progress in chemotherapy (CHT), introduction of megavoltage radiotherapy (RTX) and conservative surgery with attempts to preserve vital organs are presented. In the first period between 1962-1980 when mainly surgery was applied with orthovoltage RTX and low intensity CHT, only 20 of 74 children (27%) survived. In the second period 1981-1985 systemic CHT containing new cytostatic, megavoltage RTX and limited surgery applied in advanced cases after induction of CHT were introduced. Nineteen of 46 children (41.3%) survived. In the last period a 1986-1990 more intensive CHT with an own modified protocol VACA/VAIA and intensification phases containing cisplatinum, etoposide and/or carboplatinum were introduced. Twenty seven of 35 patients (60%) survived. Comparative analysis of the last two periods pointed to significant progress in treatment in III clinical group (IRS classification), (20.7% vs 62.9%) and parameningeal RMS (0% vs 58%). Meaningful improvement concerned also young children below 5 years of age (42.8% vs 73.9%). The main prognostic factors and treatment failures of the recent years were analyzed.
authors.affiliation: Klinika Onkologii Dzieci i Młodziezy Instytutu Matki i Dziecka w Warszawie.
authors.forename: D
authors.initials: D
authors.lastname: Perek
authors.forename: S
authors.initials: S
authors.lastname: Jurczyk-Procyk
authors.forename: J
authors.initials: J
authors.lastname: Zelazowski
authors.forename: B
authors.initials: B
authors.lastname: Dembowska-Bagińska
authors.forename: M
authors.initials: M
authors.lastname: Kozera
authors.forename: J
authors.initials: J
authors.lastname: Witkowska-Ozogowska
authors.forename: M
authors.initials: M
authors.lastname: Karwański
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009367:Neoplasm Staging; D011044:Poland; D011829:Radiation Dosage; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents